It has been reported based on animal studies that salmon calcitonin (sCT), besides hypocalcemic action, exhibits a variety of pharmacological actions. The anorectic action has been observed to ensue not only by central administration but also by peripheral injection, indicating that in clinical use to induce hypocalcemia or for other therapeutic purposes, the anorectic action may develop as a side effect. While studying the anorectic effect of [Gly
8]-sCT in rats, a derivative of sCT having rather stronger hypocalcemic potency than the mother molecule, it was found that on peripheral injection, the derivative practically lacks the anorectic effect. Thus, a pharmacological evaluation of the novel peptide was made. 1) When injected subcutaneously in rats at a dose level of 1 U/kg, sCT and the derivative induced similar patterns of hypocalcemia in either of which hypocalcemia reached a peak between 1 and 3 hr after injection. No notable difference existed between the action of the two peptides. 2) In rats which were trained to take the daily food need within 2 hr (17:00 ?? 19:00), an intracerebroventricular injection of 1 U/rat of either peptide 30 min before food presentation significantly reduced both food and water intake, causing a loss of body weight as compared with the control which received the injection of saline alone. By subcutaneous injection of 100 U/kg, sCT was also active to decrease food and water intake. The effect was found to last longer than 24 hr and to cause a marked loss in body weight. In contrast, such effects did not develop in rats treated with the derivative. 3) Both peptides were able to suppress the specific binding of
125I-sCT to the membrane fraction of rat brain and kidney. The IC50s of sCT estimated for brain and kidney were 0.71 and 1.2 nM, respectively, and those of the derivative were 3.1 and 3.2 nM, respectively. 4) A subcutaneous injection of either peptide in a dose level of 50 U/kg caused a rise by 45% in blood sugar. The results obtained herein show that the peripheral anorectic effect of sCT differ in the action mechanism from that of the central one and would be a biochemically independent action from the hypocalcemic or hyperglycemic action, and the effect is lost on replacement of the Val-residue at the 8th position by a Gly-residue, suggesting that [G1y
8]-sCT may be clinically a better substitute for sCT with less side effect.
View full abstract